Rivoglitazone
Appearance
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C20H19N3O4S |
Molar mass | 397.45 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Rivoglitazone (INN) is a thiazolidinedione derivative undergoing research for use in the treatment of type 2 diabetes.[1][2]
It is being developed by Daiichi Sankyo.
References
[edit]- ^ Schimke K, Davis TM (April 2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Current Opinion in Investigational Drugs. 8 (4): 338–344. PMID 17458185.
- ^ Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, et al. (September 2011). "A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes". Diabetes, Obesity & Metabolism. 13 (9): 806–813. doi:10.1111/j.1463-1326.2011.01411.x. PMID 21492364. S2CID 24974160.